Publicaciones en las que colabora con Bruno Carlos Sangro Gómez-Acebo (91)

2024

  1. Application of Graph Models to the Identification of Transcriptomic Oncometabolic Pathways in Human Hepatocellular Carcinoma

    Biomolecules, Vol. 14, Núm. 6

  2. Caspases compromise SLU7 and UPF1 stability and NMD activity during hepatocarcinogenesis

    JHEP Reports, Vol. 6, Núm. 8

  3. Comprehensive in silico CpG methylation analysis in hepatocellular carcinoma identifies tissue- and tumor-type specific marks disconnected from gene expression

    Journal of Physiology and Biochemistry

  4. Identification of PRMT5 as a therapeutic target in cholangiocarcinoma

    Gut

  5. New insights into the regulation of bile acids synthesis during the early stages of liver regeneration: A human and experimental study

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1870, Núm. 5

  6. Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040

    Annals of Oncology, Vol. 35, Núm. 4, pp. 381-391

  7. Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040

    Annals of Oncology, Vol. 35, Núm. 6, pp. 537-548

  8. Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment

    Clinical and Molecular Hepatology, Vol. 30, Núm. 2, pp. 177-190

  9. The Impact of Portal Hypertension Assessment Method on the Outcomes of Hepatocellular Carcinoma Resection: A Meta-Analysis of Matched Cohort and Prospective Studies

    Annals of Surgery, Vol. 280, Núm. 1, pp. 46-55

2023

  1. Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study

    The Lancet. Oncology, Vol. 24, Núm. 12, pp. 1411-1422

  2. Comprehensive analysis of epigenetic and epitranscriptomic genes’ expression in human NAFLD

    Journal of Physiology and Biochemistry, Vol. 79, Núm. 4, pp. 901-924

  3. Identification and experimental validation of druggable epigenetic targets in hepatoblastoma

    Journal of Hepatology, Vol. 79, Núm. 4, pp. 989-1005

  4. In situ detection of vaccine mRNA in the cytoplasm of hepatocytes during COVID-19 vaccine-related hepatitis

    Journal of Hepatology

  5. Liver Resection and Transplantation Following Yttrium-90 Radioembolization for Primary Malignant Liver Tumors: A 15-Year Single-Center Experience

    Cancers, Vol. 15, Núm. 3

  6. Mapping early serum proteome signatures of liver regeneration in living donor liver transplant cases

    BioFactors, Vol. 49, Núm. 4, pp. 912-927

  7. Synergistic effects of combined immunotherapy strategies in a model of multifocal hepatocellular carcinoma

    Cell Reports Medicine, Vol. 4, Núm. 4

  8. Transarterial Radioembolization Ought Not to Borrow Future Liver Function from Patients with Hepatocellular Carcinoma. But Does It?

    Journal of Vascular and Interventional Radiology

2022

  1. A new animal model of atrophy–hypertrophy complex and liver damage following Yttrium-90 lobar selective internal radiation therapy in rabbits

    Scientific Reports, Vol. 12, Núm. 1

  2. DNA Methylation Regulates a Set of Long Non-Coding RNAs Compromising Hepatic Identity during Hepatocarcinogenesis

    Cancers, Vol. 14, Núm. 9

  3. Design and validation of a tunable inertial microfluidic system for the efficient enrichment of circulating tumor cells in blood

    Bioengineering and Translational Medicine, Vol. 7, Núm. 3